RYTM

Business Context and Reporting Period

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company focused on developing precision medicines for rare neuroendocrine diseases, specifically targeting the melanocortin-4 receptor (MC4R) pathway. The company's lead asset, IMCIVREE® (setmelanotide), is approved in the U.S., EU, UK, and Canada for treating obesity and hyperphagia in patients with specific genetic deficiencies (Bardet-Biedl syndrome, POMC, PCSK1, or LEPR deficiency). The reporting period covers the fiscal year ended December 31, 2024.

Key Financial Metrics

Liquidity & Debt: The company holds approximately $320.6 million in cash and short-term investments, sufficient to fund operations into 2027. It maintains a Revenue Interest Financing Agreement (RIFA) with HealthCare Royalty Partners, with a carrying value of approximately $109.8 million (current: $1.5M; long-term: $108.3M). The company also issued Series A Convertible Preferred Stock in April 2024, raising $147.8 million in net proceeds.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased 68% to $130.1 million, driven by expanded market access in the U.S. and international markets (15+ countries) and the FDA approval of IMCIVREE for patients as young as 2 years old in December 2024.
• R&D Expense Surge: R&D expenses increased 76% to $238.0 million. This was primarily due to a one-time $92.4 million charge for acquired in-process research and development (IPR&D) assets related to the acquisition of LG Chem's oral MC4R agonist, bivamelagon.
• SG&A Increase: SG&A expenses rose 23% to $144.3 million, reflecting increased headcount to support global commercial operations and higher marketing costs.
• Net Loss Expansion: The net loss widened to $260.6 million from $184.7 million, largely attributable to the non-cash IPR&D charge and increased operational scaling.

Guidance, Outlook, and Risks

Outlook and Pipeline

• Acquired Hypothalamic Obesity: Enrollment in the pivotal Phase 3 trial is complete. Topline data is expected in the second quarter of 2025. A supplemental Japanese cohort was also completed.
• EMANATE Trial: The Phase 3 trial evaluating setmelanotide in four genetically defined cohorts (POMC/PCSK1, LEPR, SRC1, SH2B1) has completed enrollment. Topline data is anticipated in the first half of 2026.
• New Assets:
  • Bivamelagon: An oral MC4R agonist acquired from LG Chem. Phase 2 enrollment in acquired hypothalamic obesity was completed in Q1 2025.
  • RM-718: A weekly injectable MC4R agonist. Part C of the Phase 1 trial in acquired hypothalamic obesity is expected to initiate in Q1 2025.
  • Prader-Willi Syndrome (PWS): A new Phase 2 trial initiated in Q1 2025.

Risks and Contingencies

• Capital Requirements: The company anticipates continued operating losses and will need to raise additional funding in the future to support clinical trials and commercialization.
• Regulatory & Clinical Risk: Success depends on positive outcomes from ongoing Phase 3 trials. Failure to meet endpoints or delays in regulatory approval could materially impact the business.
• Reimbursement: Commercial success relies on securing adequate coverage and reimbursement from third-party payors, which remains uncertain in various jurisdictions.
• Legal Dispute: The company terminated its license agreement with RareStone Group Ltd. in 2022 for cause regarding China rights. Disputes remain unresolved, potentially impacting commercialization in that region.
• Internal Controls: A material weakness in internal controls over financial reporting (IT general controls) identified in 2023 has been remediated as of December 31, 2024.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $320.6 million cash balance to fund operations through 2027 given the high burn rate ($260M net loss in 2024).
• Phase 3 Data Readouts: Monitor the Q2 2025 topline data for the acquired hypothalamic obesity trial and H1 2026 data for the EMANATE trial, as these are critical value drivers.
• Revenue Sustainability: Assess the growth trajectory of IMCIVREE sales, noting that 74% of 2024 revenue came from the U.S. market.
• IPR&D Impact: Understand that the 2024 R&D spike included a $92.4 million non-cash charge for bivamelagon, which may not recur in the same magnitude in future periods.
• Debt Obligations: Review the terms of the Revenue Interest Financing Agreement (RIFA), including the tiered royalty structure and potential "Under Performance Payments" due in 2027 and 2029.